共 40 条
[1]
Hellstrom K.E., Hellstrom I., Principles of tumour immunity: Tumour antigens, Biologic Therapy of Cancer, pp. 35-52, (1991)
[2]
Trail P.A., Et al., Cure of xenografted human carcinomas by BR96- doxorublcin immunoconjugates, Science, 261, pp. 212-215, (1993)
[3]
Hellstrom I., Garrigues H.J., Garrigues U., Hellstrom K.E., Highly tumour-reactive, internalizing, mouse monoclonal antibodies to Ler- related cell surface antigens, Cancer Res, 50, pp. 2183-2190, (1990)
[4]
Hakomorl S., Aberrant glycosylation In tumours and tumour- associated carbohydrate antigens, Advan. Cancer Res, 52, pp. 257-331, (1989)
[5]
Garrigues J., Erson J., Hellstrom K.E., Hellstrom I., Antitumour Mab BR96 blocks cell migration and binds to lysosomal membrane glycoprotein on cell surface mlcrosplkes and ruffled membranes, J. Cell. Biol, 125, pp. 129-142, (1994)
[6]
Garrigues J., Garrigues U., Hellstrom I., Hellstrom K.E., Le' specific antibody with potent anti-tumour activity Is internalized and degraded in lysosomes, Am. J. Pathol, 142, pp. 607-622, (1993)
[7]
Willner D.E., (6-Maleimidocaproyl)hydrazone of doxorublcln- a new derivative for the preparation of immunoconjugates of doxorubicin, Bioconjugate Chem, 4, pp. 521-527, (1993)
[8]
Yelton D.E., Affinity maturation of the BR96 anticarcinoma antibody in vitro by codon-based mutagenesis, J. Immunol
[9]
Bajorath J., Three-dimensional model of the BR96 monoclonal antibody variable fragment, Bioconjugate Chem, 5, pp. 213-219, (1994)
[10]
Chang C.Y., Jeffrey P.D., Bajorath J., Hellstrom I., Hellstrom K.E., Sheriff S., Crystallization and preliminary X-ray analysis of the monoclonal anti-tumour antibody BR96 and its complex with the Lewis Y determinant, J. Molec. Biol, 235, pp. 372-376, (1994)